RT Journal Article
SR Electronic
T1 Breath biomarkers of pediatric SARS-CoV-2 infection: a pilot study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.12.04.20230755
DO 10.1101/2020.12.04.20230755
A1 Amalia Z. Berna
A1 Elikplim H. Akaho
A1 Rebecca M. Harris
A1 Morgan Congdon
A1 Emilie Korn
A1 Samuel Neher
A1 Mirna M’Farrej
A1 Julianne Burns
A1 Audrey R. Odom John
YR 2020
UL http://medrxiv.org/content/early/2020/12/07/2020.12.04.20230755.abstract
AB COVID-19 control efforts have been hampered by transmission from pre-symptomatic individuals infected with SARS-CoV2. Prolonged asymptomatic respiratory viral shedding in children has been described and may be another important reservoir for ongoing transmission. The primary diagnostic approach to identify SARS-CoV2 infection relies on qPCR of specific viral sequences from respiratory samples, which is expensive, uncomfortable, relatively slow, and susceptible to false-negative results. A rapid non-invasive method to detect mild or asymptomatic infection would have a major impact on public health campaigns to control COVID-19. We hypothesize that candidate biomarkers characterize the exhaled breath of children with SARS-CoV2 infection. To test this hypothesis, we enrolled SARS-CoV-2-infected and -uninfected children admitted to a major pediatric academic medical center and analyzed their breath volatile composition. Targeted volatiles analysis revealed that six volatile organic compounds increased significantly in SARS-CoV-2-infected children. Three aldehydes (octanal, nonanal, and heptanal) drew special attention as candidate biomarkers, because viral infections have previously been shown to induce aldehyde production. Together, these biomarkers demonstrated 100% sensitivity and 66.6% specificity. Our work provides a solid framework upon which to build a future “breathalyzer” test for SARS-CoV-2 infection in children.Competing Interest StatementThe authors have declared no competing interest.Funding StatementA.O.J. is supported by NIH/NIAID R01-AI103280, R21-AI123808, and R21-AI130584, and AOJ is an Investigator in the Pathogenesis of Infectious Diseases (PATH) of the Burroughs Wellcome Fund.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:the study was approved by the CHOP Human Research Ethics Committee (IRB 20-017503)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data referred to in the manuscript is included in the figures of the manuscript. Supplemental material is also included in the link